Udenyca

RSS

Withdrawn

This medicine's authorisation has been withdrawn

pegfilgrastim
MedicineHumanWithdrawn

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 4 February 2021, the European Commission withdrew the marketing authorisation for Udenyca (pegfilgrastim) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, ERA Consulting GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Udenyca was granted marketing authorisation in the EU on 21 September 2018 for treatment of neutropenia. The marketing authorisation was initially valid for a 5-year period. Udenyca is a biosimilar of Neulasta, which is authorised in the EU to treat neutropenia. 

The European Public Assessment Report (EPAR) for Udenyca is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (681.39 KB - PDF)

Zobacz

español (ES) (630.72 KB - PDF)

Zobacz

čeština (CS) (669.03 KB - PDF)

Zobacz

dansk (DA) (629.28 KB - PDF)

Zobacz

Deutsch (DE) (631.57 KB - PDF)

Zobacz

eesti (ET) (628.46 KB - PDF)

Zobacz

ελληνικά (EL) (689.64 KB - PDF)

Zobacz

français (FR) (631.48 KB - PDF)

Zobacz

hrvatski (HR) (648 KB - PDF)

Zobacz

italiano (IT) (628.96 KB - PDF)

Zobacz

latviešu (LV) (666.83 KB - PDF)

Zobacz

lietuvių (LT) (651.48 KB - PDF)

Zobacz

magyar (HU) (666.36 KB - PDF)

Zobacz

Malti (MT) (670.09 KB - PDF)

Zobacz

Nederlands (NL) (630.67 KB - PDF)

Zobacz

polski (PL) (671.65 KB - PDF)

Zobacz

português (PT) (630.99 KB - PDF)

Zobacz

română (RO) (649.77 KB - PDF)

Zobacz

slovenčina (SK) (668.04 KB - PDF)

Zobacz

slovenščina (SL) (662.99 KB - PDF)

Zobacz

suomi (FI) (628.69 KB - PDF)

Zobacz

svenska (SV) (665.92 KB - PDF)

Zobacz

Product information

български (BG) (1.33 MB - PDF)

Zobacz

español (ES) (1.22 MB - PDF)

Zobacz

čeština (CS) (1.26 MB - PDF)

Zobacz

dansk (DA) (1.21 MB - PDF)

Zobacz

Deutsch (DE) (1.2 MB - PDF)

Zobacz

eesti (ET) (1.2 MB - PDF)

Zobacz

ελληνικά (EL) (1.36 MB - PDF)

Zobacz

français (FR) (1.22 MB - PDF)

Zobacz

hrvatski (HR) (1.21 MB - PDF)

Zobacz

italiano (IT) (1.17 MB - PDF)

Zobacz

latviešu (LV) (1.26 MB - PDF)

Zobacz

lietuvių (LT) (1.26 MB - PDF)

Zobacz

magyar (HU) (1.39 MB - PDF)

Zobacz

Malti (MT) (1.36 MB - PDF)

Zobacz

Nederlands (NL) (1.13 MB - PDF)

Zobacz

polski (PL) (1.37 MB - PDF)

Zobacz

português (PT) (1.25 MB - PDF)

Zobacz

română (RO) (1.27 MB - PDF)

Zobacz

slovenčina (SK) (1.29 MB - PDF)

Zobacz

slovenščina (SL) (1.27 MB - PDF)

Zobacz

suomi (FI) (1.25 MB - PDF)

Zobacz

svenska (SV) (1.16 MB - PDF)

Zobacz

Íslenska (IS) (1.18 MB - PDF)

Zobacz

norsk (NO) (1.15 MB - PDF)

Zobacz
Latest procedure affecting product information:PSUSA/00002326/201901
22/11/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (617.16 KB - PDF)

Zobacz

español (ES) (574.9 KB - PDF)

Zobacz

čeština (CS) (607.36 KB - PDF)

Zobacz

dansk (DA) (575.82 KB - PDF)

Zobacz

Deutsch (DE) (575.13 KB - PDF)

Zobacz

eesti (ET) (574.97 KB - PDF)

Zobacz

ελληνικά (EL) (615.45 KB - PDF)

Zobacz

français (FR) (574.94 KB - PDF)

Zobacz

hrvatski (HR) (581.43 KB - PDF)

Zobacz

italiano (IT) (574.99 KB - PDF)

Zobacz

latviešu (LV) (610.92 KB - PDF)

Zobacz

lietuvių (LT) (583.27 KB - PDF)

Zobacz

magyar (HU) (605.81 KB - PDF)

Zobacz

Malti (MT) (609.88 KB - PDF)

Zobacz

Nederlands (NL) (575.14 KB - PDF)

Zobacz

polski (PL) (608.4 KB - PDF)

Zobacz

português (PT) (574.96 KB - PDF)

Zobacz

română (RO) (592.43 KB - PDF)

Zobacz

slovenčina (SK) (607.22 KB - PDF)

Zobacz

slovenščina (SL) (597.97 KB - PDF)

Zobacz

suomi (FI) (574.78 KB - PDF)

Zobacz

svenska (SV) (575.02 KB - PDF)

Zobacz

Íslenska (IS) (572.29 KB - PDF)

Zobacz

norsk (NO) (572.3 KB - PDF)

Zobacz

Product details

Name of medicine
Udenyca
Active substance
pegfilgrastim
International non-proprietary name (INN) or common name
pegfilgrastim
Anatomical therapeutic chemical (ATC) code
L03AA13

Pharmacotherapeutic group

  • Immunostimulants
  • Colony stimulating factors

Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Authorisation details

EMA product number
EMEA/H/C/004413

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Marketing authorisation holder
ERA Consulting GmbH

Lange Strasse 70
29664 Walsrode
Germany

Opinion adopted
25/07/2018
Marketing authorisation issued
21/09/2018
Withdrawal of marketing authorisation
04/02/2021
Revision
3

Assessment history

This page was last updated on

Share this page